I was encouraged to learn of a milestone achievement today. Mast Therapeutics of San Diego announced it has completed enrollment in its Phase III SCD EPIC trial. This trial is studying a new drug known as MST-188 or vepoloxamer in SCD patients experiencing pain crisis. By completing enrollment the company is one step closer to filing a new drug application. And because the FDA previously designated the drug candidate as an orphan designation, that places the application in position for not only accelerated approval but special marketing exclusivity. The next step is for the company to analyze the data and the expected timetable for top line results is sometime during the second quarter of 2016. Stay tuned for the top line results announcement.